Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Should be used with caution in patients with diabetes, as it may affect blood sugar levels
All medications are physician-supervised and adjusted based on individual response and safety monitoring
SURPASS-CVOT compared once-weekly tirzepatide with dulaglutide in adults with type 2 diabetes and high cardiovascular risk, showing a 9% relative risk reduction in MACE (HR 0.92, 95% CI 0.83 to 1.01)
Finally, it is hypothesised that blocking IL-23 has an impact on new bone formation
For others, it may mean reducing food noise, supporting blood sugar regulation, or continuing to experience metabolic benefits without the appetite suppression associated with higher doses
